Bluejay Diagnostics Inc

Bluejay Diagnostics reported its second quarter 2026 results, highlighting a strengthened balance sheet. At June 30, 2026, the company had approximately $9.6 million in cash and cash equivalents, up from approximately $5.2 million at December 31, 2025. During the first six months of 2026, Bluejay generated approximately $7.7 million of net cash from financing activities, including approximately $7.6 million of net proceeds from its June 2026 private placement.

Bluejay Diagnostics has completed patient enrollment in its pivotal SYMON-II multicenter clinical validation study, reaching 750 patients ahead of schedule. The study evaluates the Symphony IL-6 test for early assessment of 28-day mortality risk in sepsis patients admitted or intended for admission to intensive care units. The company expects to complete data cleaning, statistical analysis, and clinical reporting in the coming months, with results forming a key component of its planned FDA 510(k) submission for the Symphony IL-6 platform. Bluejay Diagnostics stock closed Monday at $1.21, down 16.55%, and was at $1.17 in pre-market trading, down 3.28%.